Syncom Formulation (India) Ltd.

As of June 30, 2026, Syncom Formulation (India) Ltd. carries a market capitalization of 13.40B, placing it among publicly traded companies globally. Its enterprise value stands at 13.40B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Syncom Formulation (India) Ltd. has 940.00M shares outstanding.

As of June 30, 2026, Syncom Formulation (India) Ltd. trades at a trailing price-to-earnings ratio of 15.13.

As of June 30, 2026, Syncom Formulation (India) Ltd. trades at an EV/EBITDA multiple of 15.25 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.69 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 16.52 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 13.40B versus a market cap of 13.40B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 2.03M in revenue per employee across its workforce of 2,456.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Syncom Formulation (India) Ltd. recorded 275.49M in income tax expense. That works out to an effective tax rate of 24.36, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.13B, leaving 855.30M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Syncom Formulation (India) Ltd.'s stock has gained approximately 26.54% over the past 52 weeks. The 50-day moving average sits at 20.11, while the 200-day moving average is 15.11.

Over the twelve months ended June 30, 2026, Syncom Formulation (India) Ltd. generated 4.98B in revenue and converted that into 855.30M in net income, yielding earnings per share of 0.94. EBITDA reached 878.26M, while operating income came in at 810.98M.

Over the twelve months ended June 30, 2026, Syncom Formulation (India) Ltd. posted a gross margin of 43.56, reflecting its pricing power and cost economics. The operating margin of 16.29 and net profit margin of 17.18 provide insight into operational efficiency.

Syncom Formulation (India) Ltd.'s most recent stock split took place on August 19, 2013 with a 1:35 split ratio.